Revised Definition of Light Chain MGUS and Implications for Clinical Practice

In this episode, we discuss the key abstracts in myeloma and related plasma cell disorders at ASH23 with Dr. Benjamin Derman. Here are the abstracts discussed in this episode: 

First, we will focus on a few abstracts in precursor states, MGUS. 

1.      New diagnostic criteria for light chain MGUS (IStopMM): 

             https://ash.confex.com/ash/2023/webprogram/Paper188547.html

             https://ash.confex.com/ash/2023/webprogram/Paper182661.html

2.     PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: 

https://ash.confex.com/ash/2023/webprogram/Paper191911.html

3.     ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma:

 https://ash.confex.com/ash/2023/webprogram/Paper177546.html

4.     Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma:

https://ash.confex.com/ash/2023/webprogram/Paper180766.html

5.     GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma)

 
https://ash.confex.com/ash/2023/webprogram/Paper178835.html

6.     Overall survival results of KarMMa-3 trial

https://ash.confex.com/ash/2023/webprogram/Paper178933.html

7.      GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients:

https://ash.confex.com/ash/2023/webprogram/Paper179866.html